Lizhi Cao
Overview
Explore the profile of Lizhi Cao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
8089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Wang Y, Liu J, Gao T, Cao L, Yan M, et al.
Mol Med Rep
. 2025 Feb;
31(5).
PMID: 40017126
Hepatocellular carcinoma (HCC) is a severe disease associated with a poor prognosis. The role of aberrant lipid metabolism in the development and progression of HCC necessitates detailed characterization. Sterol regulatory...
2.
Wang X, Cao L, Chang R, Shen J, Ma L, Li Y
iScience
. 2025 Jan;
28(1):111596.
PMID: 39811652
The intricate development and functionality of the mammalian heart are influenced by the heterogeneous nature of cardiomyocytes (CMs). In this study, single-cell and spatial transcriptomics were utilized to analyze cells...
3.
Chen Y, Ma L, Yan Y, Wang X, Cao L, Li Y, et al.
Mol Med Rep
. 2024 Nov;
31(2).
PMID: 39575489
Doxorubicin (DOX) is a principal chemotherapeutic agent in the domain of oncological intervention. However, its clinical application is constrained due to its severe and irreversible side effects, particularly heart damage....
4.
Cao L, Wang X, Li X, Ma L, Li Y
Mol Biotechnol
. 2024 Jan;
66(5):1229-1245.
PMID: 38236461
This research delves into the intricate relationship between hepatocellular carcinoma (HCC) and heart failure (HF) by exploring shared genetic characteristics and molecular processes. Employing advanced methodologies such as differential analysis,...
5.
Cao L, Wang X, Yan Y, Ning Z, Ma L, Li Y
Medicine (Baltimore)
. 2023 Dec;
102(51):e36705.
PMID: 38134062
Clinical data has shown that cardiovascular diseases (CVDs) have emerged as a prominent cause of mortality in individuals with hepatocellular carcinoma (HCC). This research aimed to reveal the comorbid effects...
6.
7.
Hou L, Huang K, Gong C, Luo F, Wei H, Liang L, et al.
J Clin Endocrinol Metab
. 2023 Jan;
108(8):2078-2086.
PMID: 36669772
Context: The evidence of long-term polyethylene glycol recombinant human GH (PEG-rhGH) in pediatric GH deficiency (GHD) is limited. Objective: This study aimed to examine the effectiveness and safety of long-term...
8.
Zhang Q, Wang L, Dong S, Cao L, Wu C, Liu S
Child Abuse Negl
. 2022 Oct;
134:105931.
PMID: 36302286
Background: Maternal personal history of childhood abuse has been found to predict child social-emotional problems; however, little is known about the intergenerational associations between maternal childhood abuse and child cognitive...
9.
Jiang Z, Chen X, Dong G, Lou Y, Zhang J, Cheng X, et al.
Front Pharmacol
. 2022 Aug;
13:955809.
PMID: 36034802
Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with...
10.
Yan J, Chen Z, Liang Y, Yang H, Cao L, Zhou Y, et al.
J Int Med Res
. 2020 Dec;
48(12):300060520974466.
PMID: 33305627
Patients with anti-CV2/collapsin response mediator protein (CRMP)5 antibodies present with more frequent chorea, cerebellar ataxia, uveo/retinal symptoms, and Lambert-Eaton myasthenic syndrome or myasthenia gravis. Chronic intestinal pseudo-obstruction (CIPO) is an...